ÂÜÀòÂÒÂ×

Michal is responsible for developing and implementing research strategy and for managing scientific innovation and coherence across the company’s pipeline.

Michal manages and maintains relationships with external Key Opinion Leaders (KOL's) to support mechanism of action studies, evaluation of new indications and clinical data analysis. Responsible for developing strategy for drug development, including Toxicology, Pharmacology, DMPK, and Clinical Pharmacology. Michal brings extensive experience in pharmacology and drug development.

Prior to Prilenia, Michal was the Non-Clinical Lead at the Global R&D, Teva Pharmaceuticals. In that role, Michal supported the development of numerous CNS drugs across the clinical development stages, from discovery to Phase 3 and post-marketing life cycle management. Michal led all Non-Clinical and Scientific activities for Pridopidine, Prilenia’s key asset in clinical development. Michal is a co-inventor of 10 patents/patent applications.

Michal did her post-doctoral fellowship at the Institute of Neurodegenerative Diseases, University of California, San Francisco (UCSF), under the mentorship of Nobel Laureate Stanley. B. Prusiner and has a Ph.D. from the Department of Cell Research & Immunology at Tel-Aviv University.